Yarrow Bioscience, Inc.
YARW Nasdaq
SEC CIK 1566044
Follow Yarrow Bioscience
Weekly email: filings, results
Net income
−$9.7M
EPS, diluted
−$0.43
Operating cash flow
−$90M
Operating income
−$10.7M
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $570K | −$26.5M |
| FY24 | $501K | −$39.8M |
| FY23 | $424K | −$28.5M |
| FY22 | $477K | −$23.2M |
| FY21 | $931K | −$73.3M |
| FY20 | $21M | - |
| FY19 | $443K | - |
| FY18 | $3.6M | - |
| FY17 | $4.6M | −$29.1M |
| FY16 | $674K | −$14.1M |
| FY15 | - | −$4.6M |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | −5219.1% | −4646.1% |
| FY24 | - | −8710% | −7950.9% |
| FY23 | - | −6900.5% | −6710.4% |
| FY22 | - | −7189.7% | −4865.8% |
| FY21 | - | −4179.5% | −7876.4% |
| FY20 | 93.4% | −1203% | - |
| FY19 | 100% | −21641.8% | - |
| FY18 | 100% | −2083.2% | - |
| FY17 | - | −645.9% | −634.6% |
| FY16 | - | −2126.4% | −2087.2% |
| FY15 | - | - | - |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$33.1M |
| FY24 | −$34.1M |
| FY23 | −$25.3M |
| FY22 | - |
| FY21 | −$56.4M |
| FY20 | −$137.2M |
| FY19 | −$74.5M |
| FY18 | −$69.2M |
| FY17 | −$28.2M |
| FY16 | −$2.3M |
| FY15 | −$4.2M |
| FY14 | - |
- Yarrow Bioscience
- Healthcare median
Show the numbers
| Year | Yarrow Bioscience | Healthcare median |
|---|---|---|
| FY25 | −4646.1% | −30.6% |
| FY24 | −7950.9% | −47% |
| FY23 | −6710.4% | −58% |
| FY22 | −4865.8% | −80.4% |
| FY21 | −7876.4% | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | −634.6% | −45.9% |
| FY16 | −2087.2% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |